ArticleCurrent microbiology2023
Comprehensive Analysis of the Physiological Characterization of Escherichia coli Nissle 1917.
Article in Current microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 8 citations in OpenAlex.
- Targeting IBD treatment: smart drug delivery systems for oral administration.Materials today. Bio · 2026Review
- Design and pharmacodynamic study of live biotherapeutic products with efficient degradation of branched-chain amino acids.Bioengineering & translational medicine · 2025Article
- A Simple and Rapid Method of Probiotic Bacterial Ghost Cell Preparation to Deliver Mycobacterium tuberculosis Antigen.Molecular biotechnology · 2025Article
- Comparative analysis of biofilm characterization of probioticFrontiers in microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Escherichia coli Nissle 1917 (EcN) is one of the probiotics that has drawn more attention from researchers in recent days as it extends many host beneficial effects. EcN is being used as a treatment regimen especially for gastrointestinal disorders for more than 100 years. Apart from its clinical applications in its original form, EcN is being genetically engineered to meet the therapeutic requirements which ultimately led to the gradual transformation of EcN from being a mere food supplement to a complex therapeutic agent. However, comprehensive analysis of physiological characterization of EcN is inadequate. In this study, we have systematically studied various physiological parameters and found that EcN grows very well at the normal as well as at stressful conditions such as temperature (30, 37 and 42 °C), nutritional (minimal and LB), pH (ranging from 3 to 7) and osmotic stress (0.4 M NaCl, 0.4 M KCl, 0.4 M Sucrose and salt conditions). However, EcN shows nearly onefold reduction in viability at extreme acidic conditions (pH 3 and 4). It produces biofilm and curlin very efficiently compared to the laboratory strain MG1655. Through genetic analysis we have also shown that EcN exhibits high level of transformation efficiency and greater ability to retain heterogenous plasmid. Very interestingly, we have found that EcN is highly resistant to P1 phage infection. Since, EcN is being exploited largely for its clinical and therapeutic applications, the results that we have reported here would add more value and further expand its scope in clinical and biotechnological research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.